Patents Examined by C. Azpuru
-
Patent number: 5989581Abstract: The present invention is dealing with a drug delivery system, preferably in a ring-shaped form suitable for vaginal administration, for the simultaneous release of a progestogenic steroid compound and an estrogenic steroid compound in a fixed physiological ratio over a prolonged period of time. The drug delivery system comprises at least one compartment comprising a thermoplastic polymer core containing the mixture of the progestogenic and estrogenic compounds and a thermoplastic polymer skin, the progestogenic compound being initially dissolved in the polymer core material in a relatively low degree of supersaturation.Type: GrantFiled: April 8, 1998Date of Patent: November 23, 1999Assignee: Akzo Nobel N.V.Inventor: Rudolf Johannes Joseph Groenewegen
-
Patent number: 5843469Abstract: A method for preventing, ameliorating, and/or treating memory and other cognitive disorders associated with aging, such as Age-Associated Memory Impairment (also known as Age-Related Cognitive Decline), and other age-related impairments of, and/or changes in, cognitive function. The method comprises administering to a subject a therapeutically effective amount of a lipid-soluble thiamine or a prodrug thereof in an amount averaging from about 0.02 to about 0.5 grams per day per 70 kg body weight over a period of three months or longer.Type: GrantFiled: April 11, 1997Date of Patent: December 1, 1998Inventor: William J. McEntee
-
Patent number: 5837228Abstract: A bioerodible controlled release dosage form is disclosed comprising a polymer formed by condensing beneficial agents having a hydroxyl functionality of two or more with diketene acetals or divinyl ethers which delivers beneficial agents to a biological environment of use. A statistically significant portion of the beneficial agent is covalently bonded within the polymer matrix.Type: GrantFiled: September 2, 1992Date of Patent: November 17, 1998Assignee: Merck & Co., Inc.Inventors: Chung Shih, Gaylen M. Zentner, Randall V. Sparer, R. Lee Seward
-
Patent number: 5501856Abstract: Presented are a controlled-release pharmaceutical preparation for intra-ocular implant to be applied to the interior of the eye after a surgical operation for disorders in retina/vitreous body or for glaucoma, which is produced by homogeneously dispersing an anti-inflammatory agent or a cell proliferation antagonist in certain polylactic acid and forming it into a particular shape; and a method for the prevention of the recurrence of said disorders or glaucoma after a surgical operation therefor.Type: GrantFiled: November 27, 1991Date of Patent: March 26, 1996Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Akira Ohtori, Masako Andoh, Yasushi Morita
-
Patent number: 5496555Abstract: A cleansing composition useful for the skin or hair comprising a surfactant, a green colorant, a dicarbanalide, and a color stabilzing system which is comprised of a sorbitan like compound and a polyethylene glycol.Type: GrantFiled: July 21, 1994Date of Patent: March 5, 1996Assignee: Colgate-Palmolive CompanyInventor: Dennis Colwell
-
Patent number: 5466725Abstract: The present invention relates to anti-viral materials. These anti-viral materials have a pool of anti-viral agents acting in cooperation with certain plasticizers to maintain and increase the anti-viral agents efficacy. These anti-viral materials may be used to make surgical gloves, condoms, surgical clothes, surgical operative fields, finger stalls, aprons, bibs and caps.Type: GrantFiled: December 4, 1991Date of Patent: November 14, 1995Assignee: Baxter International, Inc.Inventors: Jean Kersten, Yves Delmotte
-
Patent number: 5429821Abstract: A transplant comprising a core of a viable, physiologically active cells coated with a non-fibrogenic alkaline earth metal alginate free from fibrogenic amounts of fucose, sulfate, phloroglucinol and protein moieties, having a mannuronate to guluronate molar ratio of from 1.2 to 6. The coating protects the core from host immunological destruction after transplantation. The coating is sufficiently permeable to permit the diffusion of nutrients and cell products through the coating.A process for coating the transplant core comprising coating the core with alginate substantially free from fibrogenic compounds and reacting the alginate coating with alkaline earth metal cations comprising calcium ions or magnesium ions or mixture thereof to form an alkaline earth metal alginate coating.Type: GrantFiled: May 29, 1992Date of Patent: July 4, 1995Assignee: The Regents of the University of CaliforniaInventors: Randel E. Dorian, Kent C. Cochrum, Susan A. Jemtrud
-
Patent number: 5425948Abstract: The invention relates to pharmaceutical compositions for the treatment and prevention of cutaneous and oral mucous membrane inflammations comprising 18.beta.-glycyrrhetic acid, benezophenanthridine alkaloids and optionally a suitable metallic salt.Type: GrantFiled: April 6, 1993Date of Patent: June 20, 1995Assignee: Kemiprogress s.r.l.Inventor: Aldo Olivieri
-
Patent number: 5385738Abstract: The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.Type: GrantFiled: March 4, 1992Date of Patent: January 31, 1995Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Yoshiya Yamahira, Keiji Fujioka, Shigeji Sato, Yoshihiro Takada
-
Patent number: 5384333Abstract: A bio-injectable drug composition which provides long term drug release. The drug composition is made up of a pharmaceutically active agent in a biodegradable polymer matrix, where the polymer matrix is a solid at temperatures in the range 20.degree. to 37.degree. C. and is flowable at temperatures in the range 38.degree. to 52.degree. C.Type: GrantFiled: March 17, 1992Date of Patent: January 24, 1995Assignee: University of MiamiInventors: Patricia A. Davis, Scott Cousins
-
Patent number: 5378469Abstract: The present invention provides improved collagen threads and methods of making and using such threads, including the production of yarn, as well as braided, knitted, and woven articles of manufacture, comprising such threads.Type: GrantFiled: October 7, 1991Date of Patent: January 3, 1995Assignee: Organogenesis, Inc.Inventors: Paul D. Kemp, Robert M. Carr, Jr., John G. Maresh, John Cavallaro, Jerome Gross
-
Patent number: 5374427Abstract: An implantable active substance depot material which contains a glass ionomer cement and one or more chemotherapeutic agents. The active substance depot materials ensure an initially high release rate of the active substance therein and subsequently a discharge of the active substance in small doses until complete depletion of the deposited active substance has occurred.Type: GrantFiled: December 10, 1992Date of Patent: December 20, 1994Assignee: Thera Patent GmbH & Co. KGInventors: Wolfgang Stille, Gabriele Gentschew, Peter Reitz, Thomas Erben, Werner Zollner, Klaus-Peter Stefan
-
Patent number: 5362498Abstract: The present invention relates to a process for preparing a bioadhesive sustained-release pharmaceutical dosage form, characterized in that:a) at least a part of the active principles is mixed with a quantity of natural proteins representing at least 50% by weight of active principle, and with 0.5 to 10% of a hydrophilic polymer,b) the mixture obtained at the end of step a is subjected to granulation in the presence of approximately 60.degree. strength alcohol, followed by drying to bring it to a moisture content of approximately 3%.c) the granules thereby obtained, after sizing, are mixed with standard formulation excipients, especially ballast materials, lubricants, flavorings and sweeteners,d) the mixture obtained at the end of step c, is subjected to tabletting for the purpose of obtaining bioadhesive sustained-release tablets.It also relates to a pharmaceutical dosage form displaying long-lasting properties of adhesiveness to the mucosae.Type: GrantFiled: February 1, 1993Date of Patent: November 8, 1994Inventor: Jean-Marc Aiache
-
Patent number: 5362758Abstract: Aqueous solutions for treating inflammations of the eye, comprising: from about 0.03-3 weight percent of piroxicam; an effective amount of a buffer; from about 0 to about 1 weight percent of a wetting agent; from about 0 to about 5 weight percent of a pH adjusting agent; from about 0 to about 5 weight percent of a tonicity agent; an effective amount of a preservative; from about 0 to about 3 weight percent of a demulcent polymer; from about 0 to about 40 weight percent of a complexing agent; and from about 0 to about 0.1 weight percent of a stabilizer; and having a pH between about 7 and about 10.Type: GrantFiled: October 30, 1992Date of Patent: November 8, 1994Assignee: Pfizer Inc.Inventor: Imran Ahmed
-
Patent number: 5362495Abstract: The present invention has for its object an insert material used for widening the gingival sulcus, substantially without bleeding or oozing, particularly in order to make a cast for a dental prosthesis.According to the invention, this material takes the form of a biocompatible paste which is injectable for external use and preferably hydrophilic, whose viscosity is of between about 13000 and about 30000 Pascals.second.Application: dental surgery.Type: GrantFiled: December 10, 1991Date of Patent: November 8, 1994Inventor: Patrick Lesage
-
Patent number: 5342622Abstract: The present invention provides pharmaceutical or veterinary implants which, when subdermally administered releases a peptide or protein in a substantially continuous manner. The implant includes the peptide or protein and an excipient encased within a polymeric coating which is permeable, swellable and, at normal physiological pH, is non-rupturing, non-dissolving and does not degrade over the useful life the implant. The coating forms a release rate limiting barrier. All of the components used to make the implant are of a biocompatible nature. The implant is particularly useful for the sustained release of proteins or peptides for regulating the hormonally controlled reproductive cycle in sheep.Type: GrantFiled: October 31, 1990Date of Patent: August 30, 1994Assignees: The State of Victoria, Victorian College of Pharmacy Ltd., Monash Medical CentreInventors: Alan H. Williams, Linton D. Staples, William J. Thiel, Richard C. Oppenheim, Iain J. Clarke
-
Patent number: 5328691Abstract: A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-gamma-linolenyl-glycerol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.Type: GrantFiled: June 1, 1992Date of Patent: July 12, 1994Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5326568Abstract: The method of tissue-specific delivery of therapeutic agents via a bio-oncotic pump which includes the steps of furnishing an implantable element which is biodegradable in situ within human tissue. Such an element defines a series of respective concentric shells having different therapeutic agents disposed upon each of the shells such that the outermost shell and associated agents will be delivered earliest, while the innermost shell and its agents will be delivered last. The material of the biodegradable element is selected from the group of materials including processed sheep dermal collagen, Hench's bioglass, fibrinogen, polyimino-carbonate, and polylactic acid. A vaso-inductive agent is integrated into the surface of the element. Selected groups of therapeutic agents are incorporated into the element, which is followed by the subcutaneous implantation and securing of said element into the human tissue at the site of interest.Type: GrantFiled: April 30, 1992Date of Patent: July 5, 1994Inventor: Vincent C. Giampapa
-
Patent number: 5314685Abstract: Anhydrous formulations useful for administering lipophilic, pharmaceutically active agents to hosts in need of such treatment processes for preparing these formulations, pharmaceutical compositions based upon these formulations, and the use of these formulations to administer lipophilic, pharmaceutically active agents to a host. The lipophilic agent to be administered is solubilized in a hydrophilic vehicle which makes up at least part of the anhydrous formulation. Preferably, the lipophilic agent is present in the hydrophilic vehicle in a supersaturated or near saturated amount. Preferred pharmaceutical compositions based upon the formulations according to the present invention are useful in treating skin dermatoses such as psoriasis.Type: GrantFiled: May 11, 1992Date of Patent: May 24, 1994Assignee: Agouron Pharmaceuticals, Inc.Inventors: Praveen Tyle, Kenneth R. Freebern
-
Patent number: 5300294Abstract: Invented is a Method of Treating Prostatic Adenocarcinoma by employing a steroid 5-.alpha.-reductase inhibiting compound or a combination of steroid 5-.alpha.-reductase inhibiting compounds.Type: GrantFiled: June 27, 1990Date of Patent: April 5, 1994Assignee: SmithKline Beecham CorporationInventor: Randall K. Johnson